Aspirin protects against Barrett's esophagus

July 23, 2012, American Gastroenterological Association

Aspirin use appears to reduce the risk of Barrett's esophagus (BE), the largest known risk factor for esophageal cancer, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

"The protective effect of aspirin use appears robust because the analyses suggests a dose-response relationship in which high-dose aspirin was significantly associated with decreased Barrett's esophagus risk," said Chin Hur, MD, MPH, of the Massachusetts General Hospital Institute for Technology Assessment and lead author of this study. "It would not be advisable at this time for patients to start taking aspirin, particularly at higher doses, if preventing Barrett's esophagus is the only goal. However, if additional data confirms our findings and an individual at high risk for development of Barrett's esophagus and esophageal cancer also could derive additional benefits, most notably cardiovascular, aspirin could be a consideration."

Dr. Hur and his team of researchers analyzed characteristics of 434 BE patients for factors that might be used in screening and management. In addition to finding that those taking aspirin were 44 percent less likely to have BE, they also found that men were more than three times more likely to develop BE than women.

The incidence of esophageal cancer has been increasing at an alarming rate during the past few decades; current attempts at targeted screening for this type of cancer focus on identifying BE. Nonsteroidal anti-inflammatory drugs (), particularly aspirin, have been associated with reduced esophageal . Although there have been many studies analyzing NSAID and aspirin for esophageal cancer or BE progression to this cancer, few have explored NSAIDs for BE prevention.

Explore further: GERD-related inflammation may contribute to esophageal cancer risk

More information: Read AGA's medical position statement on the management of BE.

Related Stories

GERD-related inflammation may contribute to esophageal cancer risk

May 10, 2012
Inflammation might be an important factor in the progression from reflux to esophageal cancer, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological ...

Even low-dose aspirin may increase risk of GI bleeding

September 12, 2011
The risk of gastrointestinal (GI) bleeding needs to be considered when determining the potential preventive benefits associated with low-dose aspirin for cardiovascular disease and cancer. According to a new study in Clinical ...

Barrett's esophagus carries lower risk of malignancy than previously reported

June 16, 2011
Patients with Barrett's esophagus may have a lower risk of esophageal cancer than previously reported, according to a large, long-term study published online June 16 in the Journal of the National Cancer Institute.

Esophageal cancer risk higher in medically treated GERD patients with fewest symptoms

July 18, 2011
Medically treated patients with mild or no symptoms of gastroesophageal reflux disease (GERD) are at higher risk for developing esophageal cancer than those with severe GERD symptoms, according to a University of Pittsburgh ...

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.